A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Metabolomics measures the complete set of small molecules (metabolites) in a biological sample, providing a snapshot of the cell's biochemical activity. The two primary analytical platforms are mass spectrometry (often coupled with liquid or gas chromatography) and nuclear magnetic resonance (NMR) spectroscopy. Untargeted metabolomics aims to detect as many metabolites as possible without prior selection, while targeted metabolomics quantifies a predefined set of metabolites. Because metabolites are the downstream products of gene expression, protein activity, and environmental inputs, metabolomics captures the functional endpoint of biological processes and is particularly sensitive to rapid physiological changes.
Examine a published metabolomics dataset from a disease study (e.g., diabetes vs. healthy controls). Use MetaboAnalyst to normalize the data, perform PCA to visualize group separation, identify significantly altered metabolites, and map them onto metabolic pathways to interpret the biological significance.
Genomics maps the blueprint. Transcriptomics and proteomics map the machinery. Metabolomics maps the chemistry actually happening in the cell — the inputs, intermediates, and outputs of metabolism. Because metabolites integrate the effects of genes, enzymes, diet, drugs, and the microbiome, they provide the most direct readout of an organism's physiological state at a given moment.
The two main analytical platforms have complementary strengths. Mass spectrometry (MS), typically coupled with liquid chromatography (LC-MS) or gas chromatography (GC-MS), offers high sensitivity and broad coverage. LC-MS can detect polar and nonpolar metabolites, lipids, and other small molecules at nanomolar to micromolar concentrations. GC-MS excels for volatile compounds and requires derivatization of non-volatile metabolites. The mass spectrometer measures the mass-to-charge ratio of ionized molecules, and tandem MS (MS/MS) provides fragmentation patterns for structural identification. NMR spectroscopy is less sensitive but highly reproducible, non-destructive, and requires minimal sample preparation. NMR provides structural information directly and is particularly useful for identifying unknown compounds, though its lower sensitivity means it detects only the most abundant metabolites.
Data analysis in metabolomics follows a pipeline analogous to other omics fields. Raw spectra are processed (peak detection, alignment, normalization), features are identified (matching mass and fragmentation patterns to databases like HMDB, METLIN, and MassBank), and statistical analysis identifies metabolites that differ between conditions. PCA and partial least squares discriminant analysis (PLS-DA) are commonly used for visualization and classification. Pathway enrichment analysis maps altered metabolites onto known metabolic pathways (KEGG, MetaCyc) to interpret the biological context. The gap between detecting a feature (a peak at a particular mass and retention time) and identifying it (naming the metabolite with confidence) remains the field's biggest challenge — in many studies, 50-80% of detected features remain unidentified.
Metabolomics has found clinical applications as a biomarker discovery platform. Blood metabolite panels can discriminate disease states (cancer, diabetes, cardiovascular disease) with high accuracy, sometimes detecting changes before clinical symptoms appear. In personalized medicine, pharmacometabolomics studies how an individual's metabolic profile predicts drug response — connecting back to pharmacogenomics but at the functional level rather than the genetic level. Integration with other omics layers (genomics, transcriptomics, proteomics) through multi-omics approaches provides the most comprehensive picture of biological systems, connecting genetic variation to molecular mechanisms to phenotypic outcomes.